Skip to main content
An official website of the United States government

anti-B7-H6/anti-CD3 bispecific antibody TGI-6

A bispecific antibody directed against both natural cytotoxicity triggering receptor 3 ligand 1 (NCR3LG1; B7-H6) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-B7-H6/anti-CD3 bispecific antibody TGI-6 targets and binds to both B7-H6 on tumor cells and CD3 on T cells. This results in the cross-linking of B7-H6-expressing tumor cells and T cells, redirects cytotoxic T lymphocytes (CTLs) to B7-H6-expressing tumor cells, which leads to the CTL-mediated cell death of B7-H6-expressing tumor cells. B7-H6, a member of the B7 family of immune modulators, is expressed in a variety of tumor cell types while minimally or not expressed in normal tissues. It is a specific ligand for the natural killer (NK) cell activating receptor NKp30, and may modulate NK cell function in certain cancers.
Synonym:anti-B7-H6/CD3 bispecific antibody TGI-6
B7-H6 x CD3 bispecific antibody TGI-6
Code name:TGI 6
TGI-6
TGI6
Search NCI's Drug Dictionary